Loading organizations...
§ Private Profile · Riga, Riga, Latvia
Longenesis is a technology company.
Longenesis develops a digital platform connecting life science companies, healthcare providers, and patients for secure health data utilization. It facilitates compliant post-market research and patient engagement, establishing an ethical ecosystem for real-world data exchange to accelerate medical advancements through efficient collaboration. The platform's infrastructure streamlines data access while maintaining privacy and regulatory adherence.
Founded in 2017 by Garri Zmudze, Sergey Jakimov, and Emil Syundyukov, Longenesis emerged from observing fragmented health data hindering medical research. Their insight focused on creating a secure digital bridge to unify information, expediting innovative therapy development. The founders recognized the potential for technology to unlock vast amounts of health data for the benefit of medical progress.
The platform serves pharmaceutical companies, research institutions, and healthcare providers seeking real-world data for insights. Patients gain control over their health information, contributing to medical progress by participating in research more directly. Longenesis envisions a collaborative health data ecosystem, fostering rapid innovation for personalized, effective treatments globally.
Longenesis has raised $1.0M across 1 funding round.
Longenesis has raised $1.0M in total across 1 funding round.
Longenesis has raised $1.0M in total across 1 funding round.
Longenesis's investors include Rustam Gilfanov, LongeVC, Ilya Suharenko.
Longenesis has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in June 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2021 | $1M Seed | Rustam Gilfanov | LongeVC, Ilya Suharenko | Announced |
Longenesis is a Latvia-based medical technology startup founded in 2019 that builds a digital platform bridging healthcare institutions, life-science companies, and patients to accelerate biomedical research and improve health outcomes.[1][2][3] It offers SaaS tools for patient cohort discovery, consent management, engagement in clinical research, post-market studies, adherence programs, market access, and real-world evidence generation, serving biopharma firms, healthcare providers, biobanks, clinics, and patient organizations across the EU, MENA, U.S., South Korea, and Northern Europe.[1][2][3] The platform addresses slow, traditional biomedical research processes by enabling targeted patient identification, ethical data use, and proactive engagement in areas like cardiometabolic diseases, oncology, and infectious diseases, with over 20 healthcare partnerships, 10 life-science collaborations, and engagement of 700,000+ patients.[2][3] Early growth includes €1 million seed funding in 2021 and features in EU startup lists.[1]
Longenesis emerged in 2019 from a vision to digitize and streamline biomedical research, co-founded with involvement from biotech leaders like Insilico Medicine.[1][5] The core idea addressed the inefficiencies in stakeholder collaboration for clinical studies, leading to tools for patient consent, cohort identification, and engagement.[1] Key early traction came from partnerships with 20+ biomedical institutions, patient groups, biobanks, genomic sequencers, clinics, and health authorities across multiple regions within three years.[1] A pivotal moment was securing €1 million in seed funding in June 2021, highlighted in EU VC overviews and Latvian startup spotlights, fueling platform expansion.[1][5]
Longenesis rides the wave of digital health transformation, where real-world evidence, patient engagement, and ethical AI-driven data curation are critical for accelerating therapies amid rising chronic disease burdens and regulatory demands for patient-centric outcomes.[2][3][4] Timing aligns with post-pandemic emphasis on remote research tools and health data interoperability, boosted by EU funding like EIT Health and global biotech investments.[1][5] Market forces favoring it include exploding demand for RWE in reimbursement (e.g., oncology, infectious diseases), GDPR-compliant platforms in Europe/MENA, and partnerships bridging silos between providers and pharma.[1][3] It influences the ecosystem by standardizing digital consent and engagement, reducing research timelines, and enabling scalable studies like its Ewopharma collaboration on respiratory infections, set for 2028 results.[3]
Longenesis is poised for expansion through deeper biopharma integrations and geographic scaling, leveraging its seed momentum toward Series A amid booming RWE markets projected to grow with AI-health synergies.[1][2] Trends like personalized medicine, decentralized trials, and global data-sharing regulations will amplify its tools, potentially evolving it into a key enabler for novel therapies in underserved areas like pediatric infections.[3] Its influence may grow via more academic outputs and government ties, solidifying its role in patient-empowered research—transforming how biomedical innovation bridges data to real-world impact, much like its founding goal to digitize stagnant processes.[1][5]